Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 2
2010 4
2011 2
2012 1
2013 1
2016 1
2017 3
2018 2
2019 5
2020 19
2021 31
2022 35
2023 8
Text availability
Article attribute
Article type
Publication date

Search Results

106 results
Results by year
Filters applied: . Clear all
Page 1
Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
Abad VC, Guilleminault C. Abad VC, et al. Drugs Aging. 2018 Sep;35(9):791-817. doi: 10.1007/s40266-018-0569-8. Drugs Aging. 2018. PMID: 30058034 Review.
Phase II studies of dual orexin receptor antagonists (almorexant, lemborexant, and filorexant) have shown some improvement in sleep maintenance and sleep continuity. ...
Phase II studies of dual orexin receptor antagonists (almorexant, lemborexant, and filorexant) have shown some improvement in sleep m …
Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Citrome L, Juday T, Frech F, Atkins N Jr. Citrome L, et al. J Clin Psychiatry. 2021 Jun 1;82:20m13795. doi: 10.4088/JCP.20m13795. J Clin Psychiatry. 2021. PMID: 34077032 Free article. Clinical Trial.
In general, NNH values for lemborexant versus placebo were 10, suggesting that lemborexant is relatively tolerable. Somnolence was the most common AE, with NNH estimates of 28 (95% CI, 18-61) and 15 (95% CI, 11-22) for lemborexant 5 mg and 10 mg, respectively …
In general, NNH values for lemborexant versus placebo were 10, suggesting that lemborexant is relatively tolerable. Somnolence …
Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
Kishi T, Nishida M, Koebis M, Taninaga T, Muramoto K, Kubota N, Moline M, Sakuma K, Okuya M, Nomura I, Iwata N. Kishi T, et al. Neuropsychopharmacol Rep. 2021 Dec;41(4):450-458. doi: 10.1002/npr2.12205. Epub 2021 Sep 23. Neuropsychopharmacol Rep. 2021. PMID: 34553844 Free PMC article. Review.
When compared to suvorexant, lemborexant quickly binds to the orexin receptors. The time to reach the maximum concentration after multiple administrations is shorter for lemborexant than for suvorexant. Considering these results, we recommend 5-mg lemborexant …
When compared to suvorexant, lemborexant quickly binds to the orexin receptors. The time to reach the maximum concentration after mul …
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
In terms of acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo (SMD range: 0.36-0.83 [CINeMA estimates of certainty: high to moderate]). ...Compared with ramelteon, eszopiclone and …
In terms of acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more ef …
Lemborexant: First Approval.
Scott LJ. Scott LJ. Drugs. 2020 Mar;80(4):425-432. doi: 10.1007/s40265-020-01276-1. Drugs. 2020. PMID: 32096020 Review.
In January 2020, lemborexant also received approval in Japan for the treatment of insomnia. ...This article summarizes the milestones in the development of lemborexant leading to its first global approval....
In January 2020, lemborexant also received approval in Japan for the treatment of insomnia. ...This article summarizes the milestones …
Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M. Yardley J, et al. Sleep Med. 2021 Apr;80:333-342. doi: 10.1016/j.sleep.2021.01.048. Epub 2021 Feb 1. Sleep Med. 2021. PMID: 33636648 Free article. Clinical Trial.
In Treatment Period 1 (first six months), subjects (n = 949, Full Analysis Set) were randomized to daily placebo, lemborexant 5 mg (LEM5) or lemborexant 10 mg (LEM10). In Treatment Period 2 (second six months), placebo subjects were rerandomized to LEM5 or LEM10, an …
In Treatment Period 1 (first six months), subjects (n = 949, Full Analysis Set) were randomized to daily placebo, lemborexant 5 mg (L …
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Muehlan C, et al. Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1063-1078. doi: 10.1080/17425255.2020.1817380. Epub 2020 Oct 4. Expert Opin Drug Metab Toxicol. 2020. PMID: 32901578 Review.
Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and drugs with a distinctive profile (daridorexant) or orexin-2 receptor selectivity (seltorexant) are in development. ...Further research is neede …
Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and dru …
Hypocretins (orexins): The ultimate translational neuropeptides.
Jacobson LH, Hoyer D, de Lecea L. Jacobson LH, et al. J Intern Med. 2022 May;291(5):533-556. doi: 10.1111/joim.13406. Epub 2022 Jan 19. J Intern Med. 2022. PMID: 35043499 Review.
This has been clinically validated: currently, two Hcrt receptor antagonists are approved to treat insomnia (suvorexant and lemborexant), with a New Drug Application recently submitted to the US Food and Drug Administration for a third drug (daridorexant). ...Circuit neuro …
This has been clinically validated: currently, two Hcrt receptor antagonists are approved to treat insomnia (suvorexant and lemborexant …
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Rosenberg R, et al. JAMA Netw Open. 2019 Dec 2;2(12):e1918254. doi: 10.1001/jamanetworkopen.2019.18254. JAMA Netw Open. 2019. PMID: 31880796 Free PMC article. Clinical Trial.
RESULTS: Among 1006 participants randomized (placebo, n = 208; zolpidem, n = 263; lemborexant 5 mg, n = 266; and lemborexant 10 mg, n = 269), 869 (86.4%) were women and the median age was 63 years (range, 55-88 years). ...For nights 29 and 30, as measured using poly …
RESULTS: Among 1006 participants randomized (placebo, n = 208; zolpidem, n = 263; lemborexant 5 mg, n = 266; and lemborexant 1 …
Lemborexant.
[No authors listed] [No authors listed] 2021 Dec 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Dec 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33104322 Free Books & Documents. Review.
No information is available on the use of lemborexant during breastfeeding. Because it is about 94% bound to plasma proteins, amounts in milk are likely to be small. If lemborexant is required by the mother, it is not a reason to discontinue breastfeeding. ...
No information is available on the use of lemborexant during breastfeeding. Because it is about 94% bound to plasma proteins, amounts …
106 results